

Marianne G Guren

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7464757/marianne-g-guren-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

83
papers

2,674
citations

28
h-index

50
g-index

91
ext. papers

3,405
ext. citations

4.2
avg, IF

4.88
L-index

#	Paper	IF	Citations
83	Sex hormones and sperm parameters after adjuvant oxaliplatin-based treatment for colorectal cancer.. <i>Cancer Treatment and Research Communications</i> , 2022 , 31, 100517	2	
82	Compliance with recommended cancer patient pathway timeframes and choice of treatment differed by cancer type and place of residence among cancer patients in Norway in 2015-2016.. <i>BMC Cancer</i> , 2022 , 22, 220	4.8	
81	A Machine-Learning-Based Bibliometric Analysis of the Scientific Literature on Anal Cancer.. <i>Cancers</i> , 2022 , 14,	6.6	2
80	"Global Multidisciplinary Team Meetings": Challenging Cases Virtual Forums from the International Multidisciplinary Anal Cancer Conference (IMACC).. <i>Clinical Colorectal Cancer</i> , 2022 ,	3.8	1
79	Deep learning-based automatic delineation of anal cancer gross tumour volume: a multimodality comparison of CT, PET and MRI. <i>Acta Oncologica</i> , 2021 , 1-8	3.2	0
78	Survival trends of right- and left-sided colon cancer across four decades: a Norwegian population-based study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021 ,	4	2
77	Repeat sequential oxaliplatin-based chemotherapy (FLOX) and nivolumab versus FLOX alone as first-line treatment of microsatellite-stable (MSS) metastatic colorectal cancer (mCRC): Initial results from the randomized METIMMOX study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3556-3556	2.2	1
76	Treatment outcomes and prognostic factors after chemoradiotherapy for anal cancer. <i>Acta Oncologica</i> , 2021 , 60, 921-930	3.2	3
75	Factors associated with emergency-onset diagnosis, time to treatment and type of treatment in colorectal cancer patients in Norway. <i>BMC Cancer</i> , 2021 , 21, 757	4.8	2
74	Predicting outcomes in anal cancer patients using multi-centre data and distributed learning - A proof-of-concept study. <i>Radiotherapy and Oncology</i> , 2021 , 159, 183-189	5.3	7
73	Accurate population-based model for individual prediction of colon cancer recurrence. <i>Acta Oncologica</i> , 2021 , 60, 1241-1249	3.2	2
72	Colon and rectal cancer survival in seven high-income countries 2010-2014: variation by age and stage at diagnosis (the ICBP SURVMARK-2 project). <i>Gut</i> , 2021 , 70, 114-126	19.2	20
71	Age disparities in stage-specific colon cancer survival across seven countries: An International Cancer Benchmarking Partnership SURVMARK-2 population-based study. <i>International Journal of Cancer</i> , 2021 , 148, 1575-1585	7.5	7
70	Intensity modulated proton therapy planning study for organ at risk sparing in rectal cancer re-irradiation. <i>Acta Oncologica</i> , 2021 , 60, 1436-1439	3.2	1
69	One-year excess mortality and treatment in surgically treated patients with colorectal cancer: A EURECCA European comparison. <i>European Journal of Surgical Oncology</i> , 2021 , 47, 1651-1660	3.6	0
68	Treatment of Squamous Cell Carcinoma of the Anus, Unresolved Areas and Future Perspectives for Research: Perspectives of Research Needs in Anal Cancer. <i>Clinical Colorectal Cancer</i> , 2021 ,	3.8	2
67	Characteristics of Early-Onset vs Late-Onset Colorectal Cancer: A Review. <i>JAMA Surgery</i> , 2021 , 156, 865-874	8.4	15

66	Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2021 , 32, 1087-1100	10.3	13
65	De novo transcriptomic subtyping of colorectal cancer liver metastases in the context of tumor heterogeneity. <i>Genome Medicine</i> , 2021 , 13, 143	14.4	3
64	Increased sensitivity to SMAC mimetic LCL161 identified by longitudinal ex vivo pharmacogenomics of recurrent, KRAS mutated rectal cancer liver metastases. <i>Journal of Translational Medicine</i> , 2021 , 19, 384	8.5	1
63	Common and distinct characteristics associated with self-reported functional status in older patients with cancer receiving chemotherapy. <i>European Journal of Oncology Nursing</i> , 2021 , 54, 102033	2.8	0
62	International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2510-2518	2.2	37
61	Treatment strategies and overall survival for incurable metastatic colorectal cancer - A EURECCA international comparison including 21,196 patients from the Netherlands and Norway. <i>European Journal of Surgical Oncology</i> , 2020 , 46, 1167-1173	3.6	4
60	Re-irradiation for recurrent rectal cancer - a single-center experience. <i>Acta Oncologica</i> , 2020 , 59, 534-540	3.2	0
59	High Concordance and Negative Prognostic Impact of RAS/BRAF/PIK3CA Mutations in Multiple Resected Colorectal Liver Metastases. <i>Clinical Colorectal Cancer</i> , 2020 , 19, e26-e47	3.8	11
58	Chemotherapy During Pregnancy for Advanced Colon Cancer: A Case Report. <i>Clinical Colorectal Cancer</i> , 2020 , 19, 141-144	3.8	2
57	High symptom burden is associated with impaired quality of life in colorectal cancer patients during chemotherapy: A prospective longitudinal study. <i>European Journal of Oncology Nursing</i> , 2020 , 44, 101679	2.8	11
56	Evaluation of the stage classification of anal cancer by the TNM 8th version versus the TNM 7th version. <i>Acta Oncologica</i> , 2020 , 59, 1016-1023	3.2	2
55	Prediction of relapse-free survival according to adjuvant chemotherapy and regulator of chromosome condensation 2 (RCC2) expression in colorectal cancer. <i>ESMO Open</i> , 2020 , 5, e001040	6	0
54	Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity. <i>EBioMedicine</i> , 2020 , 59, 102923	8.8	10
53	Patient-Derived Organoids from Multiple Colorectal Cancer Liver Metastases Reveal Moderate Intra-patient Pharmacotranscriptomic Heterogeneity. <i>Clinical Cancer Research</i> , 2020 , 26, 4107-4119	12.9	30
52	International expert consensus statement regarding radiotherapy treatment options for rectal cancer during the COVID 19 pandemic. <i>Radiotherapy and Oncology</i> , 2020 , 148, 213-215	5.3	40
51	The global challenge of colorectal cancer. <i>The Lancet Gastroenterology and Hepatology</i> , 2019 , 4, 894-895	18.8	28
50	Transcriptional and functional consequences of TP53 splice mutations in colorectal cancer. <i>Oncogenesis</i> , 2019 , 8, 35	6.6	7
49	Anal cancer chemoradiotherapy outcome prediction using F-fluorodeoxyglucose positron emission tomography and clinicopathological factors. <i>British Journal of Radiology</i> , 2019 , 92, 20181006	3.4	9

48	Heterogeneous radiological response to neoadjuvant therapy is associated with poor prognosis after resection of colorectal liver metastases. <i>European Journal of Surgical Oncology</i> , 2019 , 45, 2340-2346	3.6	9
47	Changes in colorectal cancer incidence in seven high-income countries: a population-based study. <i>The Lancet Gastroenterology and Hepatology</i> , 2019 , 4, 511-518	18.8	132
46	Exploratory analyses of consensus molecular subtype-dependent associations of mutations with immunomodulation and prognosis in colorectal cancer. <i>ESMO Open</i> , 2019 , 4, e000523	6	9
45	Surgical treatment and survival from colorectal cancer in Denmark, England, Norway, and Sweden: a population-based study. <i>Lancet Oncology</i> , 2019 , 20, 74-87	21.7	57
44	Symptoms during chemotherapy in colorectal cancer patients. <i>Supportive Care in Cancer</i> , 2019 , 27, 3007-3017	3.9	17
43	Rising Incidence and Improved Survival of Anal Squamous Cell Carcinoma in Norway, 1987-2016. <i>Clinical Colorectal Cancer</i> , 2019 , 18, e96-e103	3.8	18
42	CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer. <i>Annals of Oncology</i> , 2018 , 29, 1227-1234	10.3	49
41	Treatment and Survival of Patients with Colon Cancer Aged 80 Years and Older: A EURECCA International Comparison. <i>Oncologist</i> , 2018 , 23, 982-990	5.7	10
40	Treatment and survival of rectal cancer patients over the age of 80 years: a EURECCA international comparison. <i>British Journal of Cancer</i> , 2018 , 119, 517-522	8.7	20
39	Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer. <i>Molecular Oncology</i> , 2018 , 12, 1639-1655	7.9	30
38	Phase I-III development of the EORTC QLQ-ANL27, a health-related quality of life questionnaire for anal cancer. <i>Radiotherapy and Oncology</i> , 2018 , 126, 222-228	5.3	19
37	Patient factors and quality of life outcomes differ among four subgroups of oncology patients based on symptom occurrence. <i>Acta Oncologica</i> , 2017 , 56, 462-470	3.2	31
36	Resection of synchronous liver metastases between radiotherapy and definitive surgery for locally advanced rectal cancer: short-term surgical outcomes, overall survival and recurrence-free survival. <i>Colorectal Disease</i> , 2017 , 19, 731-738	2.1	14
35	Health-related quality of life in patients with metastatic colorectal cancer, association with systemic inflammatory response and RAS and BRAF mutation status. <i>European Journal of Cancer</i> , 2017 , 81, 26-35	7.5	6
34	Target volume delineation of anal cancer based on magnetic resonance imaging or positron emission tomography. <i>Radiation Oncology</i> , 2017 , 12, 147	4.2	12
33	The normal tissue sparing potential of an adaptive plan selection strategy for re-irradiation of recurrent rectal cancer. <i>Physics and Imaging in Radiation Oncology</i> , 2017 , 3, 43-48	3.1	5
32	Preoperative chemoradiotherapy for rectal cancer and impact on outcomes - A population-based study. <i>Radiotherapy and Oncology</i> , 2017 , 123, 446-453	5.3	17
31	No Differences in Symptom Burden Between Colorectal Cancer Patients Receiving Curative Versus Palliative Chemotherapy. <i>Journal of Pain and Symptom Management</i> , 2016 , 52, 539-547	4.8	11

30	Two countries - Two treatment strategies for rectal cancer. <i>Radiotherapy and Oncology</i> , 2016 , 121, 357-363	3.3	39
29	Palliative pelvic radiotherapy for symptomatic rectal cancer - a prospective multicenter study. <i>Acta Oncologica</i> , 2016 , 55, 1400-1407	3.2	22
28	Nationwide improvement of rectal cancer treatment outcomes in Norway, 1993-2010. <i>Acta Oncologica</i> , 2015 , 54, 1714-22	3.2	51
27	Is England closing the international gap in cancer survival?. <i>British Journal of Cancer</i> , 2015 , 113, 848-60	8.7	75
26	Palliative pelvic radiotherapy for symptomatic incurable prostate cancer - A prospective multicenter study. <i>Radiotherapy and Oncology</i> , 2015 , 115, 314-20	5.3	21
25	Radiofrequency ablation of unresectable colorectal liver metastases: trends in management and outcome during a decade at a single center. <i>Acta Radiologica Open</i> , 2015 , 4, 2058460115580877	1.2	2
24	Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer. <i>European Journal of Cancer</i> , 2015 , 51, 2740-6	7.5	25
23	InterAACT: An international multicenter open label randomized phase II advanced anal cancer trial comparing cisplatin (CDDP) plus 5-fluorouracil (5-FU) versus carboplatin (CBDCA) plus weekly paclitaxel (PTX) in patients with inoperable locally recurrent (ILR) or metastatic disease.. <i>Journal of Clinical Oncology</i> , 2015 , 33, TP3792-TP3792	2.2	5
22	Palliative pelvic radiotherapy of symptomatic incurable prostate cancer - a systematic review. <i>Radiotherapy and Oncology</i> , 2014 , 110, 55-60	5.3	29
21	Reirradiation of locally recurrent rectal cancer: a systematic review. <i>Radiotherapy and Oncology</i> , 2014 , 113, 151-7	5.3	68
20	Palliative pelvic radiotherapy of symptomatic incurable rectal cancer - a systematic review. <i>Acta Oncologica</i> , 2014 , 53, 164-73	3.2	61
19	Palliative pelvic radiotherapy for symptomatic incurable prostate cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e16050-e16050	2.2	
18	Target Volume Definition in Rectal Cancer: What Is the Best Imaging Modality?. <i>Current Colorectal Cancer Reports</i> , 2013 , 9, 116-125	1	
17	Faecal incontinence after chemoradiotherapy in anal cancer survivors: long-term results of a national cohort. <i>Radiotherapy and Oncology</i> , 2013 , 108, 55-60	5.3	42
16	Patient-reported outcomes evaluating palliative radiotherapy and chemotherapy in patients with oesophageal cancer: a systematic review. <i>Acta Oncologica</i> , 2013 , 52, 679-90	3.2	20
15	Impaired health-related quality of life after chemoradiotherapy for anal cancer: late effects in a national cohort of 128 survivors. <i>Acta Oncologica</i> , 2013 , 52, 736-44	3.2	73
14	Anticipating the clinical use of prognostic gene expression-based tests for colon cancer stage II and III: is Godot finally arriving?. <i>Clinical Cancer Research</i> , 2013 , 19, 6669-77	12.9	23
13	Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. <i>Annals of Oncology</i> , 2013 , 24, 152-60	10.3	598

12	Chemoradiotherapy of anal carcinoma: survival and recurrence in an unselected national cohort. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012 , 83, e173-80	4	35
11	Sexual function in females after radiotherapy for rectal cancer. <i>Acta Oncologica</i> , 2010 , 49, 826-32	3.2	67
10	Late side effects and quality of life after radiotherapy for rectal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010 , 76, 1005-11	4	179
9	Sexual function in males after radiotherapy for rectal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010 , 76, 1012-7	4	68
8	Radiotherapy for rectal cancer is associated with reduced serum testosterone and increased FSH and LH. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008 , 70, 722-7	4	38
7	Dietary intake and nutritional indicators are transiently compromised during radiotherapy for rectal cancer. <i>European Journal of Clinical Nutrition</i> , 2006 , 60, 113-9	5.2	21
6	Quality of life and functional outcome following anterior or abdominoperineal resection for rectal cancer. <i>European Journal of Surgical Oncology</i> , 2005 , 31, 735-42	3.6	151
5	Demonstration of EGFR gene copy loss in colorectal carcinomas by fluorescence in situ hybridization (FISH): a surrogate marker for sensitivity to specific anti-EGFR therapy?. <i>Histopathology</i> , 2005 , 47, 560-4	7.3	45
4	Biochemical signs of impaired cobalamin status during and after radiotherapy for rectal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004 , 60, 807-13	4	5
3	Radiation therapy induced changes in male sex hormone levels in rectal cancer patients. <i>Radiotherapy and Oncology</i> , 2003 , 68, 249-53	5.3	41
2	Quality of life during radiotherapy for rectal cancer. <i>European Journal of Cancer</i> , 2003 , 39, 587-94	7.5	79
1	Quality of life in patients with urinary diversion after operation for locally advanced rectal cancer. <i>European Journal of Surgical Oncology</i> , 2001 , 27, 645-51	3.6	50